141 related articles for article (PubMed ID: 29949531)
1. Clinical and immunohistochemical features of primary breast cancer and metachronous ovarian and endometrial tumors.
Kryzhanivska AE; Dyakiv IB; Kyshakevych I
Exp Oncol; 2018 Jun; 40(2):124-127. PubMed ID: 29949531
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of breast and ovarian cancer subtypes in Hispanic populations from Puerto Rico.
Rodriguez-Velazquez A; Velez R; Lafontaine JC; Colon-Echevarria CB; Lamboy-Caraballo RD; Ramirez I; Mendoza A; Casbas-Hernandez P; Armaiz-Pena GN
BMC Cancer; 2018 Nov; 18(1):1177. PubMed ID: 30482165
[TBL] [Abstract][Full Text] [Related]
3. СD44+/CD24- markers of cancer stem cells in patients with breast cancer of different molecular subtypes.
Chekhun SV; Zadvorny TV; Tymovska YO; Anikusko MF; Novak OE; Polishchuk LZ
Exp Oncol; 2015 Mar; 37(1):58-63. PubMed ID: 25804234
[TBL] [Abstract][Full Text] [Related]
4. Intraocular Metastases Secondary to Breast Carcinoma Correlates With Upregulation of Estrogen and Progesterone Receptor Expression in the Primary Tumor.
Parrozzani R; Frizziero L; Testi I; Miglionico G; Perrini P; Pulze S; Pilotto E; Midena E
Invest Ophthalmol Vis Sci; 2016 Aug; 57(10):3944-8. PubMed ID: 27479811
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Metachronous Breast and Endometrial Cancers: Preroutine and Postroutine Adjuvant Tamoxifen Use.
Grzankowski KS; Szender JB; Spring-Robinson CL; Lele SB; Odunsi KO; Frederick PJ
Int J Gynecol Cancer; 2016 Oct; 26(8):1440-7. PubMed ID: 27648713
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK
Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of hormonal receptor status of malignant ovarian tumors.
Tkalia IG; Vorobyova LI; Svintsitsky VS; Nespryadko SV; Goncharuk IV; Lukyanova NY; Chekhun VF
Exp Oncol; 2014 Jun; 36(2):125-33. PubMed ID: 24980769
[TBL] [Abstract][Full Text] [Related]
8. [Survival of patients with metastatic breast cancer according to pathological types of tumors].
Sánchez R C; Acevedo C F; Petric G M; Galindo A H; Domínguez C F; León R A; Razmilic V D; Ceballos C; Espinoza F; Navarro O ME; Oddó B D; Camus A M
Rev Med Chil; 2014 Apr; 142(4):428-35. PubMed ID: 25117032
[TBL] [Abstract][Full Text] [Related]
9. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.
Arapantoni-Dadioti P; Valavanis C; Gavressea T; Tzaida O; Trihia H; Lekka I
J BUON; 2012; 17(2):277-83. PubMed ID: 22740206
[TBL] [Abstract][Full Text] [Related]
10. Ki67 expression in breast cancer. Correlation with prognostic markers and clinicopathological parameters in Saudi patients.
Elkablawy MA; Albasri AM; Mohammed RA; Hussainy AS; Nouh MM; Alhujaily AS
Saudi Med J; 2016 Feb; 37(2):137-41. PubMed ID: 26837394
[TBL] [Abstract][Full Text] [Related]
11. Risk of mortality of node-negative, ER/PR/HER2 breast cancer subtypes in T1, T2, and T3 tumors.
Parise CA; Caggiano V
Breast Cancer Res Treat; 2017 Oct; 165(3):743-750. PubMed ID: 28689363
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer prognosis is better in patients who develop subsequent metachronous thyroid cancer.
Lei K; He X; Yu L; Ni C; Chen H; Guan D; Sun K; Zou H
PLoS One; 2019; 14(5):e0215948. PubMed ID: 31042767
[TBL] [Abstract][Full Text] [Related]
13. Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer.
Domchek SM; Jhaveri K; Patil S; Stopfer JE; Hudis C; Powers J; Stadler Z; Goldstein L; Kauff N; Khasraw M; Offit K; Nathanson KL; Robson M
Cancer; 2013 Apr; 119(7):1344-8. PubMed ID: 23165893
[TBL] [Abstract][Full Text] [Related]
14. Presenting features of breast cancer differ by molecular subtype.
Wiechmann L; Sampson M; Stempel M; Jacks LM; Patil SM; King T; Morrow M
Ann Surg Oncol; 2009 Oct; 16(10):2705-10. PubMed ID: 19593632
[TBL] [Abstract][Full Text] [Related]
15. Significance of BRCA1 expression in breast and ovarian cancer patients with brain metastasis - A multicentre study.
Szarszewska M; Markowska A; Jach R; Marszałek A; Filas V; Bednarek W; Olejek A; Tomczak P; Sajdak S; Nowak-Markwitz E; Jaszczyńska-Nowinka K; Stanisławiak-Rudowicz J; Gryboś A; Chudecka-Głaz A; Gryboś M; Adamska K; Ramlau R; Markowska J; Knapp P
Adv Med Sci; 2019 Sep; 64(2):235-240. PubMed ID: 30822630
[TBL] [Abstract][Full Text] [Related]
16. Are synchronous and metachronous bilateral breast cancers different? An immunohistochemical analysis aimed at intrinsic tumor phenotype.
Senkus E; Szade J; Pieczyńska B; Zaczek A; Pikiel J; Sosińska-Mielcarek K; Karpińska A; Jassem J
Int J Clin Exp Pathol; 2014; 7(1):353-63. PubMed ID: 24427357
[TBL] [Abstract][Full Text] [Related]
17. The association between body mass index and immunohistochemical subtypes in breast cancer.
Sahin S; Erdem GU; Karatas F; Aytekin A; Sever AR; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():227-236. PubMed ID: 27756509
[TBL] [Abstract][Full Text] [Related]
18. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
Zhang HM; Zhang BN; Xuan LX; Zhao P
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
[TBL] [Abstract][Full Text] [Related]
19. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.
Azizun-Nisa ; Bhurgri Y; Raza F; Kayani N
Asian Pac J Cancer Prev; 2008; 9(4):553-6. PubMed ID: 19256737
[TBL] [Abstract][Full Text] [Related]
20. Expression of estrogen receptor, progesterone receptor, and Her-2/ neu in primary and extra-corporeal endometrial cancer.
Tangjitgamol S; Tanvanich S; Srijaipracharoen S; Manusirivithaya S
Histol Histopathol; 2013 Jun; 28(6):787-94. PubMed ID: 23255089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
